This clinical-stage pharmaceutical company develops novel therapeutics to prevent and treat the toxic effects of heavy metal exposure. They are creating orally-administered chelating agents designed to simplify treatment for patients exposed to radioactive materials and environmental toxins like lead and mercury. The company focuses on advancing solutions for heavy metal poisoning through ongoing clinical research and development programs.
Funding
Funding not disclosed
Founders
Product
Problem
Exposure to heavy metals, including lead, cadmium, and radioactive materials, poses significant health risks to communities worldwide. Current treatments for heavy metal poisoning are often ineffective or nonexistent, leaving a critical unmet need for safe and effective pharmaceuticals.
Solution
HOPO Therapeutics is developing pharmaceuticals to treat heavy metal poisoning, leveraging its expertise to address the intersection of heavy metals and human health. Their focus includes environmental pollutants like lead, cadmium, arsenic, and mercury, as well as lanthanide and radioactive actinide elements. The company's flagship drug candidate, HOPO-101, is currently in clinical development.
Target Audience
The primary target audience includes individuals and communities affected by heavy metal poisoning, as well as healthcare providers and government agencies seeking effective treatments for exposure to environmental pollutants and radiological hazards.
Features
- HOPO-101: A pharmaceutical drug candidate in clinical development for treating heavy metal poisoning.
- Focus on a range of heavy metals: Addresses exposure to environmental pollutants, lanthanides, and radioactive actinides.